海昇药业
(920656)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 254,019,438.89 | 369,056,014.58 | 446,853,145.51 | 186,341,856.34 |
| 交易性金融资产 | 155,000,000 | 70,000,000 | - | 256,000,000 |
| 应收票据及应收账款 | 34,678,009.3 | 17,248,190.75 | 18,559,556.78 | 20,631,299.26 |
| 应收账款 | 34,678,009.3 | 17,248,190.75 | 18,559,556.78 | 20,631,299.26 |
| 应收款项融资 | 9,474,522.88 | 12,311,351.22 | 9,153,560.26 | 13,134,020.7 |
| 预付款项 | 1,419,809.21 | 2,053,386.99 | 1,755,339.69 | 2,225,540.75 |
| 其他应收款合计 | 245,901.04 | 264,624.59 | 285,130.66 | 303,007.73 |
| 存货 | 29,200,763.78 | 29,281,152.04 | 24,398,125.27 | 27,051,865.27 |
| 其他流动资产 | 1,726,108.98 | 3,688,312.05 | 4,513,567.42 | 2,568,375.98 |
| 流动资产合计 | 485,764,554.08 | 503,903,032.22 | 505,518,425.59 | 508,255,966.03 |
| 非流动资产: | | | | |
| 固定资产 | 127,690,077.56 | 130,745,880.79 | 126,196,141.57 | 70,900,342.13 |
| 在建工程 | 50,572,921.47 | 43,191,569.82 | 46,416,971.95 | 56,713,845.91 |
| 无形资产 | 22,151,829.63 | 22,333,499.34 | 22,540,723.5 | 23,541,653.04 |
| 开发支出 | - | - | - | 886,158.14 |
| 长期待摊费用 | 240,120.93 | 284,233.44 | 328,345.95 | 519,247.45 |
| 递延所得税资产 | 381,607.94 | 234,993.59 | 249,240 | 207,305.58 |
| 其他非流动资产 | 3,528,413.98 | 3,033,136.98 | 1,962,118.86 | 12,905,957.39 |
| 非流动资产合计 | 204,564,971.51 | 199,823,313.96 | 197,693,541.83 | 165,674,509.64 |
| 资产总计 | 690,329,525.59 | 703,726,346.18 | 703,211,967.42 | 673,930,475.67 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 10,045,296.37 | 12,025,870.63 | 22,186,862.02 | 13,659,886.81 |
| 其中：应付票据 | - | - | 696,883.4 | 3,855,372.23 |
| 应付账款 | 10,045,296.37 | 12,025,870.63 | 21,489,978.62 | 9,804,514.58 |
| 合同负债 | 53,483.19 | 323,957.97 | 1,650,162.68 | 641,310.94 |
| 应付职工薪酬 | 16,584.56 | - | - | - |
| 应交税费 | 4,295,796.37 | 2,979,135.8 | 4,355,174.31 | 2,253,755.78 |
| 其他应付款合计 | 12,029,438.46 | 21,827,376.52 | 21,873,258.4 | 21,701,336.6 |
| 其他流动负债 | 56,324.44 | 61,583.95 | 154,542.62 | 102,174.09 |
| 流动负债合计 | 26,496,923.39 | 37,217,924.87 | 50,220,000.03 | 38,358,464.22 |
| 非流动负债: | | | | |
| 递延收益 | 196,550.56 | 274,074.2 | 351,597.84 | 429,121.48 |
| 非流动负债合计 | 196,550.56 | 274,074.2 | 351,597.84 | 429,121.48 |
| 负债合计 | 26,693,473.95 | 37,491,999.07 | 50,571,597.87 | 38,787,585.7 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 100,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 资本公积 | 325,164,553.7 | 344,827,551.37 | 344,490,549.04 | 344,418,713.16 |
| 专项储备 | 553.04 | 853.97 | 4,782.59 | - |
| 盈余公积 | 41,426,934.4 | 41,426,934.4 | 41,426,934.4 | 36,351,912.06 |
| 未分配利润 | 197,044,010.5 | 199,979,007.37 | 186,718,103.52 | 174,372,264.75 |
| 归属于母公司股东权益合计 | 663,636,051.64 | 666,234,347.11 | 652,640,369.55 | 635,142,889.97 |
| 股东权益合计 | 663,636,051.64 | 666,234,347.11 | 652,640,369.55 | 635,142,889.97 |
| 负债和股东权益合计 | 690,329,525.59 | 703,726,346.18 | 703,211,967.42 | 673,930,475.67 |
| 公告日期 | 2025-08-21 | 2025-04-25 | 2025-04-25 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |